February 16,2023 Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
February 15,2023 Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex
December 16,2021 Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV
October 28,2016 Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood
April 02,2015 FORTRESS BIOTECH (f/k/a Coronado Biosciences) FORMS NEW SUBSIDIARY, HELOCYTE, INC. (f/k/a DiaVax Biosciences) TO DEVELOP NOVEL IMMUNOTHERAPIES FOR CYTOMEGALOVIRUS
